Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Aug 27;13(1):2392897. doi: 10.1080/2162402X.2024.2392897

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

PMC Copyright notice

Figure 3. — Immunohistochemistry and DSP analysis of intravenously treated NSCLC xenografted hIL2 NOG mouse 4 (TIL^NTd-treated) and mouse 17 (TIL^STAb-treated). (a, b) expression (a) and quantification (b) of Alu-II, CD4, CD8, EGR and perforin after treatment of hIL-2 NOG xenografted mouse 4 (M4) with TIL^NTd or mouse 17 (M17) with TIL^STAb. Scale bars: 50 µm. (c) CD4 and CD8 T cell distribution by DSP from multiple circular ROI of a maximum of 500 µm within TIL^NTd- or TIL^STAb-treated tumors in non-segmented or CD4/CD8-segmented compartments. (d) Differentially expressed protein markers in ROI from tumors treated with TIL^NTd or TIL^STAb within the lymphocyte (PanCk^‒CD45⁺) compartment. Significance (FDR-adjusted p-values) is expressed relative to the FC in protein levels in TIL^STAb-treated vs. TIL^NTd-treated ROI. Markers with an FC > 2 and FDR-adjusted p-values < 0.05 in the two cohorts (TIL^STAb- or TIL^NTd-treated) are marked in bold. (e) Comparative analysis of 4-1BB, ICOS and GZMB levels measured by DSP in non-CD4/CD8-segmented or CD4 and CD8 compartments. Significance in (e) was calculated by unpaired t-test. (f) Linear regression analysis between CD4 or CD8 infiltrated T cells and 4-1BB, ICOS and GZMB in P1 primary tumor, TIL^NTd-treated M4 and TIL^STAb-treated M17 measured by DSP. R² represents goodness of fit to the model. *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001. FC, fold change; FDR, false discovery rate; ROI, regions of interest; GZMB, granzyme B.